Newron Pharmaceuticals (OTCMKTS:NWPHF) Lowered to Sell at Zacks Investment Research

Zacks Investment Research lowered shares of Newron Pharmaceuticals (OTCMKTS:NWPHF) from a hold rating to a sell rating in a research note released on Tuesday morning, reports.

According to Zacks, “Newron Pharmaceuticals SpA is a biopharmaceutical company. It focuses on the discovery and development of drugs for the treatment of central nervous system disorders and pain primarily in Italy and internationally. Newron Pharmaceuticals SpA is headquartered in Bresso, Italy. “

Newron Pharmaceuticals stock opened at $7.50 on Tuesday. The firm’s 50-day moving average is $7.46 and its 200-day moving average is $8.56. Newron Pharmaceuticals has a 1 year low of $6.55 and a 1 year high of $7.50. The company has a market cap of $133.80 million, a P/E ratio of -7.58 and a beta of 0.22.

Newron Pharmaceuticals Company Profile

Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development, manufacture, and distribution of therapies for the treatment of central and peripheral nervous system in Italy and internationally. The company offers Xadago (safinamide) for the treatment of Parkinson's disease.

Further Reading: Shanghai Stock Exchange Composite Index

Get a free copy of the Zacks research report on Newron Pharmaceuticals (NWPHF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Newron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Newron Pharmaceuticals and related companies with's FREE daily email newsletter.